SNIPR Biome Receives CARB-X Funding to Test...
CMN Briefs
Apr. 22, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
BRAIN Biotech
Main focus: Undisclosed
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: BRAIN-Engineered-Cas01 (BMC01) nuclease
Funding stage: Public (XETRA:BNN)
Location: Zwingenberg, Germany
Website: https://www.brain-biotech.com/
BRAIN Biotech is a company focused on providing solutions for industrial biotechnology. The company's engagement in the gene-editing space comes through its development of novel non-Cas9 nucleases that are being validated for gene editing in bacteria, fungi, yeast as well as in mammalian cells. While the company does not have any disclosed therapeutic programmes, the novel Cas systems may provide a way to expand into the therapeutic space.
